Insights

Strategic Board Myris Therapeutics recently expanded governance with a new board member, signaling an acceleration in strategic direction and potential for stronger partnerships or advisory networks that can be leveraged for collaboration opportunities in high-value collaborations.

DAR ADC Focus The company develops ultra-high DAR ADCs by merging traditional ADC engineering with advanced polymer chemistry, indicating a niche that may benefit from specialized service providers, materials suppliers, and CROs with expertise in linker technologies, polymer chemistry, and preclinical assessment.

Mid-sized Growth With 11-50 employees and revenue in the lower tens of millions, Myris sits in a mid-sized biotech segment that often seeks targeted partnerships, contract research, or co-development deals to scale capabilities without full in-house expansion.

Funding & Valuation Signals Recent funding status and a revenue range of 10–25 million combined with a modest funding pool suggest opportunities for strategic partnerships, licensing discussions, or additional investment conversations to accelerate pipeline progression.

Tech & Compliance Stack Adoption of enterprise tools (Salesforce, Microsoft 365, WordPress, KnowBe4) and security practices (X-XSS-Protection) implies a workflow-savvy organization receptive to vendor ecosystems, security-conscious IT procurement, and scalable collaboration platforms suitable for a heightened partner or supplier relationship program.

Similar companies to Myris Therapeutics

Myris Therapeutics Tech Stack

Myris Therapeutics uses 8 technology products and services including WordPress, Salesforce, Apple iCloud Mail, and more. Explore Myris Therapeutics's tech stack below.

  • Content Management System
  • Customer Relationship Management
  • Apple iCloud Mail
    Email
  • PHP
    Programming Languages
  • Security
  • X-XSS-Protection
    Security
  • easy pie chart
    Web Tools And Plugins

Myris Therapeutics's Email Address Formats

Myris Therapeutics uses at least 5 email formats:
Myris Therapeutics Email FormatsExamplePercentage
First.Last@biohybridsolutions.comJohn.Doe@biohybridsolutions.com
73%
First@biohybridsolutions.comJohn@biohybridsolutions.com
14%
Last@biohybridsolutions.comDoe@biohybridsolutions.com
6%
LastF@biohybridsolutions.comDoeJ@biohybridsolutions.com
7%
FLast@myristx.comJDoe@myristx.com
100%

Frequently Asked Questions

What is Myris Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Myris Therapeutics's official website is myristx.com and has social profiles on LinkedIn.

How much revenue does Myris Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Myris Therapeutics's annual revenue is estimated to be $10M - $25M.

What is Myris Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Myris Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Myris Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Myris Therapeutics has approximately 24 employees across 1 continents, including North America. Key team members include Board Director: M. M., Site Facilities And Supply Chain Manager: M. P. and Analytical Scientist: C. C. Explore Myris Therapeutics's employee directory with LeadIQ.

What industry does Myris Therapeutics belong to?

Minus sign iconPlus sign icon
Myris Therapeutics operates in the Biotechnology Research industry.

What technology does Myris Therapeutics use?

Minus sign iconPlus sign icon
Myris Therapeutics's tech stack includes WordPress, Salesforce, Apple iCloud Mail, Microsoft 365, PHP, KnowBe4, X-XSS-Protection and easy pie chart.

What is Myris Therapeutics's email format?

Minus sign iconPlus sign icon
Myris Therapeutics's email format typically follows the pattern of First.Last@biohybridsolutions.com. Find more Myris Therapeutics email formats with LeadIQ.

How much funding has Myris Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Myris Therapeutics has raised $2.9M in funding. The last funding round occurred on Dec 21, 2023.
Myris Therapeutics logo

Myris Therapeutics

Biotechnology ResearchPennsylvania, United States11-50 Employees

Myris Therapeutics, based in Pittsburgh, Pennsylvania, operates in the biotechnology research sector. It develops antibody-drug conjugates with very high drug-to-antibody ratios by combining traditional ADC design with next-generation polymer chemistry. The company maintains a compact, specialized team to advance this platform.
Positioned in the ADC development space, its work targets the biotechnology and pharmaceutical research community seeking advanced conjugate technologies. In August 2022, the company announced the appointment of Mark Murcko, Ph.D., to its board.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $2.9M

    Myris Therapeutics has raised a total of $2.9M of funding over 6 rounds. Their latest funding round was raised on Dec 21, 2023 as a Seed.

  • $10M - $25M

    Myris Therapeutics's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.